161 results about "Low intraocular pressure" patented technology

A device for passively measuring intraocular pressure of a patient including an in vivo sensor and an instrument external to the patient for remotely energizing the sensor, thereby permitting the instrument to determine the intraocular pressure. The device directly and continuously measures the intraocular pressure of a patient. The in vivo sensor in the intraocular pressure monitor includes a capacitive pressure sensor and an inductive component. An instrument, external to the patient, measures the pressure, provides readout of the pressure values and determines the intraocular pressure.

Embodiments include methods, apparatuses, and systems for reducing elevated intraocular pressure (IOP) in a patient to either prevent or treat open-angle glaucoma. Heat is applied to the trabecular meshwork in the patient's eye without damaging proteins in the trabecular meshwork. The application of heat to the trabecular meshwork has the effect of relaxing or loosening protein clogs or other inhibitors in the trabecular meshwork, which are either reducing or obstructing of the outflow of aqueous humor, thereby increasing the patient's IOP and causing ocular hypertension (OHT). By loosening or relaxing clogs or other inhibitors in the trabecular meshwork, the outflow path for aqueous humor is increased or restored, which can lower IOP and either prevent or treat glaucoma. Force may also be applied to the patient's eye to apply pressure to the trabecular meshwork to further assist in the loosening or relaxing of clogs or other inhibitors in the trabecular meshwork.

The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).

The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal.

A drainage apparatus is disclosed to reduce intraocular pressure in an eyeball that includes an anterior chamber having aqueous humor disposed therein, a cornea and a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer disposed on an exposed surface of the eyeball and under eyelids, the apparatus comprising an inlet assembly configured to be disposed at the anterior chamber of the eyeball, an outlet assembly configured to be disposed at the external surface of the eyeball, the assembly having a central chamber, a tube extending between the inlet and outlet assemblies and configured to promote fluid communication between the inlet and outlet assemblies, and control means disposed within the outlet assembly for controlling a flow of aqueous humor through the tube from the anterior chamber of the eyeball to the external surface of the eyeball, the control means further comprising a replaceable filter disposed within the central chamber of the outer member to prevent intraocular infection, the filter having a medicinal agent applied thereto for preventing occlusion of the filter or bacterial contamination by inhibiting at least one of the formation of fibrotic membranes, inflammatory membrane, or bacterial adhesions or biofilms, thereby preventing increased of intraocular pressure or infection.

The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with tafluprost, their intraocular pressure lowering effects are complemented and / or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.

The present invention provides ocular implants adapted to reside in Schlemm's canal for reducing intraocular pressure of an eye and methods for using the same. In some embodiments the ocular implants comprise a thin rod adapted and configured to extend in a curved volume in Schlemm's canal. The thin rod comprises a plurality of wave-shaped segments such that a sufficient number and amount of wave-shaped segments extend to the inner wall of the trabecular meshwork and to the outer wall of Schlemm's canal thereby keeping Schlemm's canal open.

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and / or signaling of lysyl oxidase (LOX) or a lysyl oxidase-like protease (LOXL).

Embodiments include methods, apparatuses, and systems for reducing elevated intraocular pressure (IOP) in a patient to either prevent or treat open-angle glaucoma. Heat is applied to the trabecular meshwork in the patient's eye without damaging proteins in the trabecular meshwork. The application of heat to the trabecular meshwork has the effect of relaxing or loosening protein clogs or other inhibitors in the trabecular meshwork, which are either reducing or obstructing of the outflow of aqueous humor, thereby increasing the patient's IOP and causing ocular hypertension (OHT). By loosening or relaxing clogs or other inhibitors in the trabecular meshwork, the outflow path for aqueous humor is increased or restored, which can lower IOP and either prevent or treat glaucoma. Force may also be applied to the patient's eye to apply pressure to the trabecular meshwork to further assist in the loosening or relaxing of clogs or other inhibitors in the trabecular meshwork.

An improved method for controlling intraocular pressure during ophthalmic surgery.

This invention is a system, an apparatus and a method for measuring biomechanical properties of cornea and the intraocular pressure in vivo. More than one dimensional topographic information of the cornea is recorded and analyzed before and during the fluid discharge and converted to the stress-strain relationship and other cornea parameters, for example the cornea thickness and radius of curvature, etc. The deformation of cornea is initiated by a non-contact fluid discharge whose profile is predetermined and monitored in real time. Utilizing this non-contact topographer, the true intraocular pressure can be derived from the response of the cornea due to the impact of fluid discharge and the corneal topographic parameters. One embodiment of this invention includes the use of a multiple color strobe light / multiple detector system to record the corneal topographic deformation due to the impact of fluid discharge.

The present invention provides systems and methods for reducing intraocular pressure, thereby to treat glaucoma and other disorders. The systems of the present invention include a shunt insertable across the clear cornea and a delivery device for inserting the shunt in the transcorneal position. The shunt has a body with a head at one end and a foot at the opposite end, and a channel therethrough permitting the passage of aqueous humor from the anterior chamber to the external surface of the cornea. A removable filter is positioned within the channel to regulate aqueous humor outflow and to resist the incursion of microorganisms.

An eye mounted device configured to actively evacuate fluid from the anterior chamber of the eye to an exterior region or the sclera of the eye. The device employs a miniature pump powered by a photovoltaic cell which is mounted in the clear corneal tissue and which may be curved in the same shape as the eye. One or a combination of pressure sensors and timers determine the duration the device evacuates fluid from the user's eye.

A device and system for controlling pressure via fluid exchange in the body is presented. The device and system may be used to control intraocular eye pressure. The system is comprised of four main components: a cannula, a sensor, a controller and a pump. The system works to engage in a fluid exchange which slowly increases / decreases intraocular pressure until a desired level is reached. Once the desired level is reached, the intraocular pressure is held steady and any external pressure perturbations are removed.

The present invention relates, in general, to methods of treating disorders of the eye, and, in particular, to methods of preventing or treating elevated eye pressure and glaucoma. The invention further relates to compounds and compositions suitable for use in such methods.

The invention relates to the use of Abnormal Cannabidiols in a combination with a drug selected from the group consisting of β-blockers, adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, chlolinesterase inhibitors, glutamate antagonists, prostamides and prostaglandins and the like, or pharmaceutically acceptable salts or prodrugs thereof as potent ocular hypotensives. Said combinations are particularly suitable for the management of glaucoma. In particular said Abnoral Cannibidiols are represented by formula I or formula II or formula III

The present invention relates, in general, to methods of treating disorders of the eye, and, in particular, to methods of preventing or treating elevated eye pressure and glaucoma. The invention further relates to compounds and compositions suitable for use in such methods.

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and / or signaling of connective tissue growth factor (CTGF).

Provided herein is an ophthalmic formulation that comprises a fine particle of an A1 agonist in an aqueous suspension and a manufacturing process thereof. More specifically, provided herein is a topically applied ophthalmic aqueous suspension which is obtainable by suspending a fine particle of an A1 agonist in a surfactant and preservative; a method of reduction of intraocular pressure using the formulation and a manufacturing process of the aqueous suspension thereof.

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and / or signaling of connective tissue growth factor (CTGF).

A method of mitigating an intraoperative hypotony condition using experimental calibrations of different infusion cannulas and vitrectomy probes showing the relationship between infusion pressure, cut rate, and intraocular pressure for various levels of aspiration vacuum in an ophthalmic surgical system.

The invention relates to a Schlemm canal expandable stent and combination bodies of the Schlemm canal expandable stent. The expandable stent is a hollow shell with a cylindrical surface. The cylindrical surface is composed of round continuous curved rings formed in the manner that an alloy wire is bent and then bent back. The surface of the alloy wire is coated with a coating with the thickness ranging from 10 microns to 50 microns. The coating comprises an adhesive bottom layer and a drug layer. By means of the Schlemm canal expandable stent, damage of the stent wall to the wall of a Schlemm canal can be reduced, the occurrence rate of restenosis and proliferation of a Schlemm canal cavity can be lowered, and excellent flexibility is achieved. The Schlemm canal expandable stent can enable drugs to be effectively and permanently released at a narrow diseased region, reduce serious damage of the stent wall to the wall of the Schlemm canal and ensure accurate local dosing to a target diseased point, thereby being capable of more effectively lowering the occurrence rate of restenosis of the Schlemm canal and achieving the purposes of promoting discharging of aqueous humo, reducing intraocular pressure and treating glaucoma.

An eye pressure monitor is composed of a spectacle frame with coil in it for generating an induced magnetic field, a magnetic vibrator for exciting the vibration of eye ball by external magnetic field and generating an inductive E.M.F in said coil, and a processing module for generating a signal to generate said induced magnetic field, measuring its inductive E.M.F, and sequentially obtaining the vibration information of eye ball, the resonance frequency of cornea and eye pressure.

Because vision loss in most forms of glaucoma is related to elevated IOP, most glaucoma treatment protocols are concerned with lowering IOP by increasing aqueous humor outflow. The invention utilizes electromagnetic radiation to create retraction in the iris tissue, thereby (a) reducing convexity and enlarging the drainage angle and thus the area of the anterior chamber, (b) reducing contact between the zonule fibers and the iris pigment epithelium, (c) applying greater tension to both the TM and uveoscleral outflow pathways, thereby enlarging those pathways and increasing outflow.